



# Neurology

---

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF NEUROLOGY

MAY 1998

VOLUME 50

NUMBER 5

---

SUPPLEMENT 5  
TO NEUROLOGY  
VOLUME 50

## TOLCAPONE: COMT INHIBITION FOR THE TREATMENT OF PARKINSON'S DISEASE

---

Stanley Fahn, MD

*Supplement Editor*

***Lippincott - Raven***

P U B L I S H E R S

Copyright © 1998 by the American Academy of Neurology. The views and opinions expressed in this Supplement are those of the authors and do not necessarily reflect the views of the editors of *Neurology*.

This supplement to *Neurology* was produced by Lippincott–Raven Healthcare, Division of Lippincott–Raven Publishers, Cedar Knolls, New Jersey. Its publication was sponsored by Roche, and prepared for publication, in part, by SynerMed, Califon, New Jersey. The views and opinions expressed in this supplement are those of the participants and authors and do not necessarily reflect the views of the American Academy of Neurology; Lippincott–Raven Publishers; Roche; or SynerMed.

# Neurology

Official Journal of the American Academy of Neurology

May 1998 Volume 50 Suppl 5

## Introduction

- S1 Tolcapone: COMT inhibition for the treatment of Parkinson's disease  
*S. Fahn*

## Articles

- S3 COMT inhibition: A new treatment strategy for Parkinson's disease  
*M.C. Kurth and C.H. Adler*
- S15 Highlights of the North American and European experiences  
*C.G. Goetz*
- S17 Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine  
*T.N. Chase*
- S26 Influence of COMT inhibition on levodopa pharmacology and therapy  
*C.G. Goetz*

The Editor-in-Chief, with advice from members of the Editorial Board, reviews requests for publication of symposia on topics of interest to readers of *Neurology*. The decision to publish a symposium as a supplement to *Neurology* is based on the topic, the supplement editors, and the contributors. Once a decision is made to publish a symposium as a supplement, it is not peer reviewed by the Editorial Board of *Neurology*. The individual authors are responsible for their own contributions, and the supplement editors are responsible for the overall quality of the supplement.

Supplement to *Neurology*. ISSN 0028-3878. Published monthly by Lippincott-Raven Publishers, 12107 Insurance Way, Hagerstown, MD 21740. Business offices are located at 227 East Washington Square, Philadelphia, PA 19106-3780. Periodicals postage paid at Hagerstown, MD, and at additional mailing offices.

Academy members should send address changes and subsequent inquiries to the American Academy of Neurology, 2221 University Ave. S.E., Suite 335, Minneapolis, MN 55414 (or call 612-623-8115). Non-Academy members should send address changes and subscription inquiries to Lippincott-Raven Publishers, Subscription Department, 12107 Insurance Way, Hagerstown, MD 21740; Call 1-800-638-3030; Fax 301-824-7390; in Maryland, call collect, 301-714-2300.

Subscription rates for 1998: Personal subscription, U.S. and possessions, \$210.00; foreign, \$310.00 (includes Mexico). PLEASE ADD 7% CANADIAN GST FOR ALL CANADIAN SUBSCRIPTIONS (Registration No.: 130876246); institutional, U.S., \$283.00; foreign, \$387.00. Special rates for students, interns, and residents per year: U.S., \$126.00; Canada, \$147.00; foreign, \$253.00. Single copies \$36.00 prepaid. In JAPAN: Please contact our exclusive agent: MEDSI, 1-2-13 Yushima, Bunkyo-ku, Tokyo 113, Japan.

- S31 Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers  
*Karin M. Jorga*
- S39 Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment  
*C.H. Waters, M. Kurth, P. Bailey, L.M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, and the Tolcapone Stable Study Group*
- S46 Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients  
*H. Baas, A.G. Beiske, J. Ghika, M. Jackson, W.H. Oertel, W. Poewe, and G. Ransmayr on behalf of the study investigators*
- S54 Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial  
*A.H. Rajput, W. Martin, M.-H. Saint-Hilaire, E. Dorflinger, and S. Pedder*

SPECIAL PROJECTS: Contact Lippincott-Raven Healthcare, 2 Ridgedale Avenue, Suite 300, Cedar Knolls, NJ 07927. 800-796-0646; Fax (973) 285-5595.

ADVERTISING REPRESENTATIVE: Roger Soderman, Metro Publishers Service Inc., P.O. Box 223, Westwood, NJ 07675-0223. 800-555-5473; FAX: (201) 772-0134.

PROFESSIONAL NOTICES AND REPRINTS AVAILABLE: Contact Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106.

*Neurology* is indexed in Index Medicus, Excerpta Medica, Biological Abstracts, Psychological Abstracts, and Current Contents (Life Sciences and Clinical Medicine).

POSTMASTER: Send address changes to NEUROLOGY, 12107 Insurance Way, Hagerstown, MD 21740.

All rights reserved. Copyright © 1998 by the American Academy of Neurology. Except as authorized in the accompanying statement, no part of *Neurology* may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without the publisher's written permission. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the American Academy of Neurology for libraries and other users registered with the Copyright Clearance Center Transactional Reporting Service, provided that the per-copy fee of \$3.00 is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. Call (508) 750-8400 or fax (508) 750-4744 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This authorization does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.



# Neurology<sup>®</sup>

**50 (5 Suppl 5)**  
*Neurology* 1998;50;S54-S30

**This information is current as of May 1, 1998**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/50/5_Suppl_5.citation.full">http://n.neurology.org/content/50/5_Suppl_5.citation.full</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

